Tags

Type your tag names separated by a space and hit enter

In vitro effectivity of three approved drugs and their synergistic interaction against Leishmania infantum.
Biomedica. 2020 05 01; 40(Supl. 1):89-101.B

Abstract

INTRODUCTION

Leishmaniasis remains one of the neglected tropical diseases. Repurposing existing drugs has proven to be successful for treating neglected tropical diseases while combination therapy is a strategic alternative for the treatment of infectious diseases. Auranofin, lopinavir/ritonavir, and sorafenib are FDA approved drugs used in the treatment of diverse diseases by acting on different essential biological enzymes.

OBJECTIVE

To evaluate the effects of monotherapy and combined therapies with the three drugs against Leishmania infantum.

MATERIALS AND METHODS

We compared the leishmanicidal effects of the three drugs on promastigotes in vitro as regards the parasite count, the drug concentration providing a half-maximal response, and the ultrastructural changes of the parasite. We determined the fractional inhibitory concentration index of combined drugs in two ways, as well as the activity of the three drugs together to establish their synergetic effect.

RESULTS

The monotherapy with the three drugs was effective with auranofin showing the best leishmanicidal effect (EC50=1.5 μM), whereas sorafinib reduced parasite growth at EC50=2.5 μM. The scanning electron microscopy of promastigotes from all treated media showed distortion in the shape with loss of flagella and bleb formation. Acidocalcinosis was evident by transmission electron microscopy with all treatments suggesting apoptosis. Treatment with lopinavir/ritonavir showed signs of autophagy. The two-way combination of the drugs led to additive interactions while the combination of the three drugs showed synergistic action.

CONCLUSION

Each drug when used as monotherapy against Leishmania spp. was effective, but the combination therapy was more effective than the individual drugs due to the additive or synergistic effects.

Authors+Show Affiliations

Medical Parasitology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt. imanabouelnaga@hotmail.com.Medical Parasitology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt. roshykareem@gmail.com.Medical Parasitology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt. nermine_mogahed@yahoo.com.

Pub Type(s)

Journal Article

Language

eng spa

PubMed ID

32463611

Citation

Abou-El-Naga, Iman Fathy, et al. "In Vitro Effectivity of Three Approved Drugs and Their Synergistic Interaction Against Leishmania Infantum." Biomedica : Revista Del Instituto Nacional De Salud, vol. 40, no. Supl. 1, 2020, pp. 89-101.
Abou-El-Naga IF, Mady RF, Fawzy Hussien Mogahed NM. In vitro effectivity of three approved drugs and their synergistic interaction against Leishmania infantum. Biomedica. 2020;40(Supl. 1):89-101.
Abou-El-Naga, I. F., Mady, R. F., & Fawzy Hussien Mogahed, N. M. (2020). In vitro effectivity of three approved drugs and their synergistic interaction against Leishmania infantum. Biomedica : Revista Del Instituto Nacional De Salud, 40(Supl. 1), 89-101. https://doi.org/10.7705/biomedica.4891
Abou-El-Naga IF, Mady RF, Fawzy Hussien Mogahed NM. In Vitro Effectivity of Three Approved Drugs and Their Synergistic Interaction Against Leishmania Infantum. Biomedica. 2020 05 1;40(Supl. 1):89-101. PubMed PMID: 32463611.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro effectivity of three approved drugs and their synergistic interaction against Leishmania infantum. AU - Abou-El-Naga,Iman Fathy, AU - Mady,Rasha Fadly, AU - Fawzy Hussien Mogahed,Nermine Mogahed, Y1 - 2020/05/01/ PY - 2018/12/28/received PY - 2020/5/29/entrez PY - 2020/5/29/pubmed PY - 2020/5/29/medline KW - Leishmania infantum KW - drug synergism KW - apoptosis KW - autophagy SP - 89 EP - 101 JF - Biomedica : revista del Instituto Nacional de Salud JO - Biomedica VL - 40 IS - Supl. 1 N2 - INTRODUCTION: Leishmaniasis remains one of the neglected tropical diseases. Repurposing existing drugs has proven to be successful for treating neglected tropical diseases while combination therapy is a strategic alternative for the treatment of infectious diseases. Auranofin, lopinavir/ritonavir, and sorafenib are FDA approved drugs used in the treatment of diverse diseases by acting on different essential biological enzymes. OBJECTIVE: To evaluate the effects of monotherapy and combined therapies with the three drugs against Leishmania infantum. MATERIALS AND METHODS: We compared the leishmanicidal effects of the three drugs on promastigotes in vitro as regards the parasite count, the drug concentration providing a half-maximal response, and the ultrastructural changes of the parasite. We determined the fractional inhibitory concentration index of combined drugs in two ways, as well as the activity of the three drugs together to establish their synergetic effect. RESULTS: The monotherapy with the three drugs was effective with auranofin showing the best leishmanicidal effect (EC50=1.5 μM), whereas sorafinib reduced parasite growth at EC50=2.5 μM. The scanning electron microscopy of promastigotes from all treated media showed distortion in the shape with loss of flagella and bleb formation. Acidocalcinosis was evident by transmission electron microscopy with all treatments suggesting apoptosis. Treatment with lopinavir/ritonavir showed signs of autophagy. The two-way combination of the drugs led to additive interactions while the combination of the three drugs showed synergistic action. CONCLUSION: Each drug when used as monotherapy against Leishmania spp. was effective, but the combination therapy was more effective than the individual drugs due to the additive or synergistic effects. SN - 2590-7379 UR - https://www.unboundmedicine.com/medline/citation/32463611/In_vitro_effectivity_of_three_approved_drugs_and_their_synergistic_interaction_against_Leishmania_infantum L2 - https://www.revistabiomedica.org/index.php/biomedica/article/view/4891 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.